The potent pulmonary vasodilating property of atrial natriuretic factor (ANF) may alter gas exchange in patients with COPD. We examined the hemodynamic and gas exchange responses to intravenous infusion of ANF (0.01 and 0.03 ng/min/kg body weight) in eight stable patients with COPD studied during spontaneous breathing, using the inert gas elimination technique. When compared with baseline, ANF infusion was associated with a dose-dependent decrease in pulmonary artery pressure (from 27.3 ± 2.5 to 23.9 ± 1.8 and 20.2 ± 1.7 mm Hg, respectively) and a dose-dependent increase in blood flow perfusing poorly ventilated and unventilated units (VA/Q <0.1: from 5.80 ± 2.05 to 7.25 ± 2.5 and 12.0 ± 5.4 percent of total blood flow, respectively; p=0.02). However, PaO2 remained unchanged (70.2 ± 3.6, 68.1 + 3.8 65.4 ± 3.5 mm Hg, respectively) because of a significant increase in minute ventilation (VE) from 8.6 ± 0.8 to 9.6 ± 0.8 and 10.3 + 0.7 L/min (p<0.002). Six additional COPD patients receiving intravenously administered ANF at the same dosages were studied during controlled mechanical ventilation using right heart Accumulating evidence now suggests that atrial natriuretic factor (ANF) plays an important role in both fluid volume and circulatory homeostasis in patients with COPD. In patients with COPD and pulmonary hypertension, the secretion of this peptide is enhanced,"2 and short-term administration of synthetic ANF has been shown to decrease pulmonary artery pressure and to increase cardiac output and ventilation.2'3 Because the pulmonary vasodilator action of ANF results from attenuation of hypoxic pulmonary vasoconstriction,4 changes in ventilationperfusion (VA/Q) relationships may be associated with increased circulating levels of the peptide. However, the effects of ANF on gas exchange and on the distribution of ventilation-perfusion ratios have not been specifically addressed in human lung dis- 94010 Creteil, France catheterization. In these patients, pulmonary vasodilation was associated with a significant increase in venous admixture (from 12.7 ± 2.4 to 14.4 ± 2.9 and 17.5 ± 3.5 percent of total blood flow, respectively; p<0.02), and a dose-dependent reduction in arterial Po2 (from 117 ± 17 to 110 + 15 and 96.4 ± 8.8 mm Hg, respectively; p<0.05). The present results show that ANF infusion is associated with alterations in the VA/Q relationship in patients with COPD. However, a decrease in arterial oxygenation may be prevented by an increase in VE. (Chest 1994; 106:118-24) eases. In the present report, we questioned whether ANF infusion could alter gas exchange and ventilation-perfusion relationships in patients with COPD. For this purpose, we studied eight spontaneously breathing patients with COPD receiving intravenously administered ANF, using the multiple inert gas elimination technique.5 In addition, we examined the effects of ANF infusion on pulmonary hemodynamics and gas exchange in six patients with COPD studied during controlled mechanical ventilation at a fixed volume.
The potent pulmonary vasodilating property of atrial natriuretic factor (ANF) may alter gas exchange in patients with COPD. We examined the hemodynamic and gas exchange responses to intravenous infusion of ANF (0.01 and 0.03 ng/min/kg body weight) in eight stable patients with COPD studied during spontaneous breathing, using the inert gas elimination technique. When compared with baseline, ANF infusion was associated with a dose-dependent decrease in pulmonary artery pressure (from 27.3 ± 2.5 to 23.9 ± 1.8 and 20.2 ± 1.7 mm Hg, respectively) and a dose-dependent increase in blood flow perfusing poorly ventilated and unventilated units (VA/Q <0.1: from 5.80 ± 2.05 to 7.25 ± 2.5 and 12.0 ± 5.4 percent of total blood flow, respectively; p=0.02). However, PaO2 remained unchanged (70.2 ± 3.6, 68.1 + 3.8 65.4 ± 3.5 mm Hg, respectively) because of a significant increase in minute ventilation (VE) from 8.6 ± 0.8 to 9.6 ± 0.8 and 10.3 + 0.7 L/min (p<0.002). Six additional COPD patients receiving intravenously administered ANF at the same dosages were studied during controlled mechanical ventilation using right heart Accumulating evidence now suggests that atrial natriuretic factor (ANF) plays an important role in both fluid volume and circulatory homeostasis in patients with COPD. In patients with COPD and pulmonary hypertension, the secretion of this peptide is enhanced,"2 and short-term administration of synthetic ANF has been shown to decrease pulmonary artery pressure and to increase cardiac output and ventilation.2'3 Because the pulmonary vasodilator action of ANF results from attenuation of hypoxic pulmonary vasoconstriction,4 changes in ventilationperfusion (VA/Q) relationships may be associated with increased circulating levels of the peptide. However, the effects of ANF on gas exchange and on the distribution of ventilation-perfusion ratios have not been specifically addressed in human lung dis- (Gould TA 2000) . Pressure values were averaged by electronic integration throughout at least three respiratory cycles and zero was referenced at the midchest level while patients were lying in a comfortable semirecumbent position. Thermodilution cardiac outputs were determined in triplicate using a 9520-A cardiac output computer (Edwards Laboratories, Santa Ana, Calif). Derived hemodynamic parameters were calculated as follows: cardiac index (CI)=cardiac output/body surface area (L/min/m2); systemic vascular resistance (SVR)=Pra-Pra/CI (mm Hg/L/min/m2); and pulmonary vascular resistance (PVR) =Ppa-Ppw/CI (mm Hg/L/min/m2).
Simultaneous mixed venous and arterial samples were drawn to determine blood gas tension and pH (ABL 30, Radiometer, Copenhagen). The hemoglobin concentration and hemoglobin oxygen saturation were measured using an OSM3 hemoximeter (Radiometer). Combination of CI with arterial and mixed venous oxygen contents allowed the calculation of arterial oxygen transport and oxygen uptake (Vo2). Venous admixture was calculated using Berrgren's equation. The alveolar-arterial oxygen pressure difference P(A-a)02 was calculated as (PB-47)-FIo2-(PACO2/ R+PAO2), where PB is the barometric pressure and FIo2, the fraction of inspired oxygen. The respiration exchange ratio (R) was assumed not to vary during the study. Since the patients were studied after a fasting night while receiving a 5 percent solution of dextrose intravenously, we used a value of R=0.85.6
Continuous ventilation-perfusion distribution was assessed using the multiple inert gas elimination technique, as described previously.7,8 Briefly, six inert gases with various blood solubilities (sulfur hexafluoride or SF 6, ethane, cyclopropane, halothane, ether, and acetone) were equilibrated in 5 percent dextrose, and this mixture was then infused at a rate of 5 ml/min in a peripheral vein. At the start of the infusion, the patients were connected to a heated, specially designed mixing box through a tightly adjusted face mask and a two-way valve. After 30 min of mixture infusion, 15 ml of heparinized blood was drawn from the pulmonary and systemic arteries for inert gas analysis in gas-tight glass syringes (Becton Dickinson, Rutherford, NJ), while expired gas was simultaneously collected from the mixing box. The VE was then measured by connecting the two-way valve to a Douglas bag for 2 min. The blood samples were equilibrated with N2 in a heated bath at 370C for 45 min. The equilibrated and expired gas samples were analyzed for SF6 with an electron capture detector (Packard 429, Packard Instruments, Downers Grove, Ill) and for the other five gases with a flame ionization detector (Packard).
The blood solubility coefficients of the six gases were determined for each patient. The partial pressures of the inert gases in the arterial and mixed venous samples were derived from the equilibrated samples and the measured solubilities. Retention-solubility and excretion-solubility curves were constructed, from which the best approximation of the ventilation-perfusion distributions was determined by computer-assisted analysis. Shunt was considered as VA/Q <0.005, and low VA/Q areas were considered as VA/Q <0.1, excluding shunt.
In the six mechanically ventilated patients, the inert gas elimination technique was not used and gas exchange was assessed by venous admixture calculation.
Protocol
After cardiac catheterization, spontaneously breathing patients were allowed to rest for at least 60 min before the beginning of the study, to obtain steady-state conditions. Baseline hemodynamic, gasometric, and VA/Q distribution measurements were recorded. Human synthetic ANF (Novabiochem, Lauifelfingen, Switzerland) was then infused via a peripheral vein at the incremental rates of 10 and 30 ng/min/kg body weight during 2 successive 30-min periods. At the end of each infusion period, hemodynamic, gasometric, and VA/Q distribution measurements were similarly recorded. A similar protocol was performed in mechanically ventilated patients, except for VA/Q distribution measurements.
The protocol was approved by the hospital's ethics committee, and informed consent was obtained from each patient or his Plasma ANF concentration increased from 120 ± 8 picogram (pg)/ml during baseline condition to 511 ± 98 pg/ml, and to 1,812 ± 327 pg/ml in response to 10 and 30 ng/kg/min of an intravenous ANF infusion, respectively.
The hemodynamic changes are summarized in Table 1 . The observed reductions of Ppa and PVR index were dose-dependent, while reduction of Psa, Pra, and Ppw only occurred at the highest ANF infusion rate. The decrease in mean Ppa at this high infusion rate was significantly greater than the decrease in mean Ppw (7.1±1.7 vs 3±0.6 mm Hg; p=0.02).
As depicted in Table 2 , there was a dose-dependent increase in VE in response to ANF infusion, which was mainly related to an increase in tidal volume (VI). This was associated with a parallel and significant reduction of PaCO2 and pH, with no change in PaO2. Arterial oxygen delivery remained constant, while an increase in Vo2 occurred at the highest ANF infusion rate. Despite the absence of change in PaO2, a significant widening in the P(A-a)02 (Table 2 ) and several alterations in the ventilation-perfusion relationship were observed, which are summarized in Table 3 . Fraction of blood flow perfusing total low VA/Q areas increased in a dose-dependent manner in response to ANF infusion, with a widening of the log distribution of blood flow and a progressive shift of mean blood flow to the left. Figures 1 and 2 show the progressive alterations of the distribution of ventilation-perfusion ratios observed in two patients during ANF infusion. At the highest ANF infusion rate, variations of Vo2 were positively related to increases in \JE (Fig 3) . Effects of Atrial Natriuretic Factor Infusion in Mechanically Ventilated Patients Plasma ANF concentration increased from 175 + 13.5 pg/ml during baseline condition to 561 + ly increased as a consequence of increased cardiac output. 163 pg/ml and to 2,224 ± 410 pg/ml in response to 10 and 30 ng/min/kg of an intravenous ANF infusion, respectively.
As shown in Table 4 Increase in minute ventilation (L/min) COPD.
In the present study, ANF infusion significantly decreased Ppa and the PVR index, increased the P(A-a)02, and induced a consistent worsening of VA/Q matching in stable, spontaneously breathing patients. In patients studied at a fixed VE, ANF infusion was associated with a significant decrease in pulmonary artery pressure and an increase in venous admixture. All these alterations are consistent with a partial release of hypoxic pulmonary vasoconstriction, which should lead to a reduction in PaO2. The importance of ANF-induced pulmonary vasodilation may have been overestimated in the present study by a concomitant passive vascular unloading related to increased diuresis. However, the fact that mean Ppa decreased to a greater extent than mean Ppw indicates pulmonary vasodilation as the major mechanism leading to the observed reduction in Ppas.
While PaO2 effectively decreased in mechanically ventilated patients, inconstant changes in PaO2 were observed in spontaneously breathing patients (Fig  1 and 2) , who all experienced consistent increases in VE in response to ANF infusion. In addition, the increase in pH observed in these patients very likely modified the hemoglobin-oxygen dissociation curve, so that the consequence on SaO2 of a minor change in PaO2, if any, was completely blunted. Thus, an increase in VE apparently appeared to counterbalance the deleterious effects of ANF infusion on arte-rial oxygenation. This observation is in agreement with the effects of increasing alveolar ventilation in lung models with various parallel or series inequalities.I'
The effects of numerous vasodilators on gas exchange have been previously addressed in patients with COPD studied in different clinical conditions.12-25 Various results have been reported because of the complex interactions between pulmonary vasodilation and alterations of cardiac output, mixed venous Po2 (Pvi02) or VE. In stable hypoxemic, hypercapnic patients, nitroglycerin 12,22 as well as nifedipine16"8"9'22 have been shown to worsen gas exchange and reduce PaO2, despite marked increases in ventilation'8"19 or significant decreases in PaCO2, or both.'2"9'22 Conversely, hydralazine or urapidil not alter gas exchange, and may even improve PaO2 15, 17, 20, [23] [24] [25] Notably, a beneficial effect of hydralazine on arterial oxygenation has been attributed, at least partly, to the marked increase in VE (up to 32 percent) observed with this drug.'7 In our spontaneously breathing patients, VE rose in a dose-dependent manner, by 11 and 22 percent, respectively, in response to increasing ANF infusion rates. The precise mechanism by which ANF increased VE remains speculative. Because bronchodilation has been described in response to intravenous infusion of ANF,2627 a direct effect of ANF on bronchomotor tone may have been evoked in our patients. Although we did not measure lung mechanics, this hypothesis seems, however, unlikely. First, the lack of change in distribution of ventilation suggests that no change in bronchomotor tone occurred. Second, the marked increase in Vo2 during ANF infusion and the significant relationship observed between the variations of VE and of Vo2 rather suggest that increased ventilation was related to an active muscular process, requiring a marked energy expenditure. Indeed, the lack of change in Vo2 in mechanically ventilated patients indicates that increased Vo2 in spontaneously breathing patients was the consequence and not the cause of increased VE. This observation is in agreement with previous reports performed in patients with COPD studied during a hyperventilation challenge. [28] [29] [30] It has been previously suggested that hydralazine increases VE by increasing central ventilatory drive. 23 Other studies performed in normal men indicate that the stimulatory effect of hypotension on ventilation is consistent with a central interaction of baroreceptor and chemoreceptor input.3' Whether the respiratory effect of ANF is the consequence of a direct action of the peptide on the central respiratory drive or is mediated by some indirect and complex mechanisms involving different peripheral baroreceptors or chemoreceptors cannot be elucidated in the present study. Of note is that the lack of change in PaCO2 in normal men studied during ANF infusion32 argues against a direct action of the peptide on central respiratory drive.
Despite this increase in VE, none of our patients complained of dyspnea. As previously noticed during hydralazine therapy,'9 or during voluntary hyperventilation,30 dyspnea or fatigue, or both, may however appear in patients with more severe disease or during more prolonged or higher dosage regimens. In conclusion, the fact that increasing plasma ANF concentrations in patients with COPD is associated with only minor effects on arterial oxygenation seems to us of clinical relevance for possible future therapeutic applications.
